NIH/National Institute of Allergy and Infectious Diseases

Medical research

Probiotic markedly reduces S. Aureus colonization in phase 2 trial

A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. The new study, reported in The ...

Oncology & Cancer

Experimental cancer vaccine shows promise in animal studies

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious ...

Diseases, Conditions, Syndromes

Monoclonal antibody prevents malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody ...

Immunology

Monoclonal antibody reduces asthma attacks in urban youth

A National Institutes of Health clinical trial has found that a monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone ...

HIV & AIDS

Experimental mRNA HIV vaccine safe, shows promise in animals

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of ...

Diseases, Conditions, Syndromes

Lung autopsies of COVID-19 patients reveal treatment clues

Lung autopsy and plasma samples from people who died of COVID-19 have provided a clearer picture of how the SARS-CoV-2 virus spreads and damages lung tissue. Scientists at the National Institutes of Health and their collaborators ...

page 2 from 40